{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:21:07Z","timestamp":1773922867822,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T00:00:00Z","timestamp":1499904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00428-017-2189-9","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T22:46:17Z","timestamp":1499899577000},"page":"589-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization"],"prefix":"10.1007","volume":"471","author":[{"given":"Ant\u00f3nio","family":"Pol\u00f3nia","sequence":"first","affiliation":[]},{"given":"Guilherme","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"issue":"4785","key":"2189_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"8","key":"2189_CR2","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"MF Press","year":"1997","unstructured":"Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ (1997) HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15(8):2894\u20132904","journal-title":"J Clin Oncol"},{"issue":"11","key":"2189_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"1","key":"2189_CR4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3322\/caac.21203","volume":"64","author":"C DeSantis","year":"2013","unstructured":"DeSantis C, Ma J, Bryan L, Jemal A (2013) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52\u201362","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2189_CR5","first-page":"127","volume":"37","author":"S Steinman","year":"2007","unstructured":"Steinman S, Wang J, Bourne P, Yang Q, Tang P (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2\/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37(2):127\u2013134","journal-title":"Ann Clin Lab Sci"},{"key":"2189_CR6","doi-asserted-by":"crossref","unstructured":"Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, Paredes J, Schmitt F Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol 42(10):1438\u20131446","DOI":"10.1016\/j.humpath.2010.08.024"},{"key":"2189_CR7","doi-asserted-by":"crossref","unstructured":"Polyak K Heterogeneity in breast cancer. J Clin Invest 121(10):3786\u20133788","DOI":"10.1172\/JCI60534"},{"issue":"4","key":"2189_CR8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","volume":"133","author":"GH Vance","year":"2009","unstructured":"Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133(4):611\u2013612","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2189_CR9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/PDM.0b013e318064c72a","volume":"16","author":"RR Tubbs","year":"2007","unstructured":"Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP (2007) Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 16(4):207\u2013210","journal-title":"Diagn Mol Pathol"},{"key":"2189_CR10","doi-asserted-by":"crossref","unstructured":"Miller DVJR, Lingle WL, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA (2004) Focal HER2\/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 intergroup adjuvant trial. J Clin Oncol 22(14S)","DOI":"10.1200\/jco.2004.22.90140.568"},{"issue":"6","key":"2189_CR11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","volume":"136","author":"KH Allison","year":"2011","unstructured":"Allison KH, Dintzis SM, Schmidt RA (2011) Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 136(6):864\u2013871","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2189_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","volume":"27","author":"WM Hanna","year":"2013","unstructured":"Hanna WM, Ruschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2013) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27(1):4\u201318","journal-title":"Mod Pathol"},{"issue":"5","key":"2189_CR13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","volume":"25","author":"MC Chang","year":"2012","unstructured":"Chang MC, Malowany JI, Mazurkiewicz J, Wood M (2012) 'Genetic heterogeneity' in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases. Mod Pathol 25(5):683\u2013688","journal-title":"Mod Pathol"},{"issue":"31","key":"2189_CR14","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2189_CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/hupa.2002.30185","volume":"33","author":"M Kobayashi","year":"2002","unstructured":"Kobayashi M, Ooi A, Oda Y, Nakanishi I (2002) Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol 33(1):21\u201328","journal-title":"Hum Pathol"},{"issue":"12","key":"2189_CR16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.MP.0000038462.62634.B1","volume":"15","author":"EK Latta","year":"2002","unstructured":"Latta EK, Tjan S, Parkes RK, O'Malley FP (2002) The role of HER2\/neu overexpression\/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15(12):1318\u20131325","journal-title":"Mod Pathol"},{"key":"2189_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1746-1596-3-41","volume":"3","author":"H Nitta","year":"2008","unstructured":"Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM (2008) Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 3:41","journal-title":"Diagn Pathol"},{"key":"2189_CR18","doi-asserted-by":"crossref","unstructured":"Fabi A, Di Benedetto A, Metro G, Perracchio L, Nistico C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 17(7):2055\u20132064","DOI":"10.1158\/1078-0432.CCR-10-1920"},{"issue":"4","key":"2189_CR19","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/bcr2128","volume":"10","author":"RM Tamimi","year":"2008","unstructured":"Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67","journal-title":"Breast Cancer Res"},{"key":"2189_CR20","doi-asserted-by":"crossref","unstructured":"Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12(4):207","DOI":"10.1186\/bcr2607"},{"issue":"12","key":"2189_CR21","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/jcp.2006.045377","volume":"60","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, Ellis IO (2007) An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol 60(12):1300\u20131306","journal-title":"J Clin Pathol"},{"issue":"1","key":"2189_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/jcp.54.1.20","volume":"54","author":"H Denley","year":"2001","unstructured":"Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO (2001) Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 54(1):20\u201324","journal-title":"J Clin Pathol"},{"issue":"2","key":"2189_CR23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","volume":"13","author":"W Hanna","year":"2007","unstructured":"Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2\/neu in breast cancer--a rare event. Breast J 13(2):122\u2013129","journal-title":"Breast J"},{"issue":"1","key":"2189_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00129039-200403000-00003","volume":"12","author":"J Andersson","year":"2004","unstructured":"Andersson J, Linderholm B, Bergh J, Elmberger G (2004) HER-2\/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 12(1):14\u201320","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"2189_CR25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00428-016-1903-3","volume":"468","author":"A Polonia","year":"2016","unstructured":"Polonia A, Leitao D, Schmitt F (2016) Application of the 2013 ASCO\/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Virchows Arch 468(4):417\u2013423","journal-title":"Virchows Arch"},{"issue":"7","key":"2189_CR26","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48\u2013e72","journal-title":"Arch Pathol Lab Med"},{"key":"2189_CR27","doi-asserted-by":"crossref","unstructured":"Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espie M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de The H, Bertheau P Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer 104(11):1739\u20131746","DOI":"10.1038\/bjc.2011.135"},{"key":"2189_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13059-015-0657-6","volume":"16","author":"CK Ng","year":"2015","unstructured":"Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, Reis-Filho JS (2015) Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol 16:107","journal-title":"Genome Biol"},{"key":"2189_CR29","doi-asserted-by":"crossref","unstructured":"Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12(5):R75","DOI":"10.1186\/bcr2645"},{"issue":"2","key":"2189_CR30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1309\/J9VXABUGKC4Y07DL","volume":"124","author":"JT Lewis","year":"2005","unstructured":"Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW (2005) Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124(2):273\u2013281","journal-title":"Am J Clin Pathol"},{"key":"2189_CR31","doi-asserted-by":"crossref","unstructured":"Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138(1):99\u2013108","DOI":"10.1007\/s10549-013-2444-y"},{"issue":"7","key":"2189_CR32","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","volume":"25","author":"H Seol","year":"2012","unstructured":"Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY (2012) Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 25(7):938\u2013948","journal-title":"Mod Pathol"},{"key":"2189_CR33","doi-asserted-by":"crossref","unstructured":"Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat 158(1):99\u2013111","DOI":"10.1007\/s10549-016-3856-2"},{"key":"2189_CR34","doi-asserted-by":"crossref","unstructured":"Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO, Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93\u201399","DOI":"10.1136\/jclinpath-2014-202571"},{"issue":"19","key":"2189_CR35","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265\u20134274","journal-title":"J Clin Oncol"},{"issue":"16","key":"2189_CR36","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672","journal-title":"N Engl J Med"},{"issue":"18","key":"2189_CR37","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","volume":"24","author":"N Robert","year":"2006","unstructured":"Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786\u20132792","journal-title":"J Clin Oncol"},{"issue":"6","key":"2189_CR38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"L Gianni","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640\u2013647","journal-title":"Lancet Oncol"},{"issue":"33","key":"2189_CR39","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744\u20133752","journal-title":"J Clin Oncol"},{"key":"2189_CR40","doi-asserted-by":"publisher","unstructured":"Polonia A, Eloy C, Pinto J, Braga AC, Oliveira G, Schmitt F (2017) Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough? Histopathology. doi: 10.1111\/his.13208","DOI":"10.1111\/his.13208"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-017-2189-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-017-2189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T21:38:35Z","timestamp":1659217115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-017-2189-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s00428-017-2189-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}